Open the Window of opportunity for the therapy of Rheumatoid arthritis –AESKULISA® CCP enables early, accurate and efficient diagnosis of RA. Experience how easy and efficient anti-CCP testing can be – easily integrate anti-CCP-testing in your daily working routine.
Developed for the early and specific diagnosis of RA AESKULISA® CCP provides maximum specificity of 95,8 % and sensitivity of 95,2 %. The high specificity of AESKULISA® CCP supports the clinicians to clearly
differentiate rheumatoid arthritis from other types of arthritis, in an early phase of the disease.
Besides its high specificity anti-CCP antibodies have been revealed to be predictive markers for RA: they may be detected in about 50-60% of patients with early RA usually after 3-6 months of symptoms (Nell et al.). Moreover studies have shown that anti-CCP can even be detected years before the first symptoms of RA. Since most of the bony damage
occurs in the first two years in 90% of patients early treatment is extremely important and can slow down disease progression.
Moreover, anti-CCP antibodies are predictive for a severe course of the disease: several studies have shown that anti-CCP positive early RA patients develop a more erosive disease than those without anti-CCP. Developed according to “THE ONE” concept AESKULISA® CCP gives you the opportunity to integrate CCP analysis easily in your routine testing, even performed in a variety of automated systems.
The features give you the possibility for a parallel ELISA testing of RF antibodies, which is still the only serological test included in the ACR criteria.
|
